表紙
市場調查報告書
商品編碼
944090

2019年冠狀病毒疾病(COVID-19)-管道和臨床試驗分析-2020年4月

Coronavirus Disease 2019 (COVID-19) - Pipeline and Clinical Trial Analysis - April 2020

出版日期: | 出版商: GlobalData | 英文 53 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

在生物製藥行業中,正在努力應對冠狀病毒感染(COVID-19)帶來的挑戰,世界各地的許多公司都在參與開發用於治療和預防的疫苗的競賽。製藥行業很早就開始研究COVID-19的病原體,但總體研發受到了不利影響,各個疾病領域的臨床試驗日程和監管機構的判斷都被推遲了。在COVID-19治療劑領域,已經被批准用於其他適應症的候選藥物正成為主流,並且被認為是可能最先獲得COVID-19治療劑批准的產品之一是一種IL-6抑製劑,已經作為免疫疾病的治療藥物上市。從2020年第一季度到第二季度,被推遲的臨床試驗數量穩步增長。到2020年下半年,似乎每個公司都將加緊努力以彌補這一延遲,但要完全克服這一困難是困難的。

本報告調查了COVID-19治療劑的全球銷售渠道和臨床試驗的狀況,研究和開發的最新趨勢,有希望的治療劑和疫苗,臨床試驗的狀況以及主要聯盟。提供諸如COVID-19對臨床試驗時間表和批准的影響之類的信息。

報告摘要

  • 即將發佈的最有希望的COVID-19治療劑和疫苗的概況,包括SWOT分析,臨床試驗概述和可用數據概述
  • 臨床試驗的狀態,包括開發治療劑和疫苗的方法
  • 建立共識的趨勢,引起公眾關注的公私夥伴關係
  • 專家對COVID-19治療藥物研發的考慮
  • 分析COVID-19大流行對各個疾病地區和地區的臨床試驗時間表的影響
  • 與大流行相關的監管機構批准延遲的評估
  • 對本報告中主題的結果進行投票

內容

目錄

  • COVID-19治療藥物研發的最新趨勢
  • 有前途的藥物正在開發中
  • 有希望的疫苗正在開發中
  • COVID-19治療藥物臨床試驗
  • 與發展有關的主要聯盟
  • COVID-19對臨床試驗時間表和監管批准的影響

主要發現

附錄

  • 調查方法
  • 縮寫
  • 相關報告
  • 來源
  • 關於作者
  • 關於全球數據
  • 聯繫我們
目錄
Product Code: GDHCHT072

The biopharmaceutical industry has risen to meet the challenge posed by this novel virus: hundreds of companies across the globe have entered the race to develop a treatment and a preventive vaccine. While the industry has shown its mettle by immediately initiating research on agents for COVID-19, the progress of R&D in general has been adversely impacted, with delays in clinical trial timelines and regulatory decisions across disease areas.

Over the coming months, as trial data readouts become available, frontrunners will emerge in both the therapeutic and preventive categories. Currently, the therapeutics space is dominated by candidates already approved for other disease indications; one of these products, an IL-6 inhibitor already marketed for an immunology indication, is well positioned to win the first regulatory approval for COVID-19. The number of clinical trial delays has been steadily increasing throughout Q1 and into Q2 2020. As activity begins to pick up later in the year, trial sponsors might strive to make up for lost time, but the extensive delays will be difficult to overcome entirely.

Scope

  • Profiles of the most promising treatments and vaccines in the pipeline for COVID-19, including SWOT analyses, an overview of trials, and summaries of available data
  • An overview of the clinical trials landscape, including discussion of the approaches being adopted for therapeutic and vaccine development
  • Highlights in deal-making trends, particularly public-private partnerships
  • Proprietary expert insights on COVID-19 R&D obtained by GlobalData's investigative journalism team
  • Analysis of the impact of the outbreak on clinical trial timelines across disease areas and geographies
  • Assessment of regulatory delays associated with the pandemic
  • GlobalData poll results on topics covered in the report

Reasons to Buy

  • Stay abreast of COVID-19 R&D

Table of Contents

Table of Contents

  • COVID-19 R&D Update
  • Promising Therapies in Development
  • Promising Vaccines in Development
  • COVID-19 Clinical Trials
  • Key Development Partnerships
  • Impact of COVID-19 on Trial Timelines and Regulatory Approvals

Key Findings

Appendix

  • Methodology
  • Abbreviations
  • Related Reports
  • Sources
  • About the Authors
  • About GlobalData
  • Contact Us